Feasibility and tolerance of pulsed dose rate interstitial brachytherapy

Pree, C. de; Popowski, Youri; Weber, Damien Charles; Nouet, Philippe; Rouzaud, Michel; Kurtz, John M.

doi:10.1016/s0360-3016(98)00525-2

Cited by 37 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute severe skin and oral mucosa effects were seen in 6.8% and 13.6% of patients, respectively. Acute mucositis (grade 2 or 3) after PDR iBT in 23.5-25% of patients was also reported by others [5,19].…”

Section: Discussionsupporting

confidence: 72%

“…Both LDR and HDR BT have long been used for head and neck tumors [1, 3, 7, 8, 12-15, 17, 23, 25]. Recently, PDR BT was reported to be an effective and safe therapy, also performed postoperatively, as well as a unique treatment for reirradiated head-and-neck tumors [5,16,[18][19][20]24]. We also demonstrated the feasibility of PDR iBT and PDR cBT in such patients.…”

Section: Discussionmentioning

confidence: 59%

“…In the series of de Pree et al [5] (with 41.1 Gy median dose, 0.5 Gy dp), 5.9% of patients (1/17) had local soft tissue necrosis. In the study by Strnad et al [19], soft-tissue and bone necrosis occurred in 4.3% (2/47; 40 treated definitively) of head-and-neck cancer patients administered PDR BT alone (D ref 50 Gy) or combined with EBRT (D ref 24 Gy), 0.5 or 0.7 Gy dp delivered every hour.…”

Section: Parameter Mean (Range)mentioning

confidence: 90%

“…1 Gy dp we used in nearly all curatively treated patients might have increased the risk of toxicity. In all aforementioned studies [5,16,18,19], PDR was delivered at dp of 0.4-0.7 Gy. There are no well-founded recommendations for PDR dp available yet.…”

Section: Parameter Mean (Range)mentioning

confidence: 99%

See 3 more Smart Citations

Preliminary Report of Pulsed Dose Rate Brachytherapy in Head-and-Neck Cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 59%

Section: Parameter Mean (Range)mentioning

confidence: 90%

Section: Parameter Mean (Range)mentioning

confidence: 99%

See 2 more Smart Citations

Preliminary Report of Pulsed Dose Rate Brachytherapy in Head-and-Neck Cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…de Pree et al [20] presented a series of 43 patients treated with PDR brachytherapy, but only 2 cases had primary EC. Overall, the dose per pulse varied between 0.4 and 1 Gy/h.…”

Section: Clinical Experiencementioning

confidence: 99%

Pulsed-Dose Rate Brachytherapy for the Treatment of Endometrial Cancer

Felice

Caiazzo²,

Benevento³

et al. 2017

Oncology

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most frequent gynecologic malignancy. The aim of this review is to outline clinical practice recommendations, to suggest a technical solution, and to advise doses selection for pulsed-dose rate (PDR) brachytherapy in EC. Electronic bibliographic databases, including PubMed, clinicaltrials.gov, and the American Society of Clinical Oncology (ASCO) Meeting Library, were searched for articles in English. Clinical guidelines and systematic reviews were also considered. The appropriate therapeutic approach should consider risk factors for tumor relapse and PDR brachytherapy and have a convincing role in this multidisciplinary scenario. Performing PDR brachytherapy in EC requires robust training and experience.

show abstract

Contemporary role of modern brachytherapy techniques in the management of malignant thoracic tumors

Harms¹,

Becker²,

Krempien³

et al. 2001

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Sole brachytherapy for carcinoma of the lung is most often performed using high-dose-rate (HDR) remote afterloading equipment, which delivers the treatment within the tracheobronchial tree in an outpatient setting. It provides excellent, rapid palliation in advanced stages, and can also be used selectively for curative intent in early stages. In better-performance patients, fractionated external beam radiation therapy (EBRT) is preferred to brachytherapy as an initial treatment because it appears to provide a modest gain in survival, and more sustained palliation. In patients with centrally located tumors and limited extent of disease, the combination of external and endoluminal irradiation enables curative treatment options. Intraoperative brachytherapy may complement standard adjuvant treatment in incompletely resected, unresectable, or medically inoperable patients, and has the potential to improve local control in selected cases. Due to the rarity of the disease, the role of endoluminal brachytherapy in the treatment regimen of tracheal neoplasms is not yet clearly defined. The risk of fatal bleeding after endoluminal brachytherapy appears to be correlated with tumor localization and fraction size, but in the majority of cases fatal bleeds are caused by progression of local disease. The use of a distanceable applicator provides a central positioning of the source, prevents the delivery of high-contact doses to the mucosa, and may reduce toxicity. The standard technique for interstitial brachytherapy after breast-conserving surgery and adjuvant EBRT is the use of low-dose-rate (LDR) brachytherapy, but it may also be applied by means of pulsed-dose-rate (PDR) or HDR techniques. Prospective trials comparing different boost techniques and indications are needed to define more precisely the subgroup of patients who are most suitable for interstitial brachytherapy. Reirradiation of chest wall local recurrences using brachytherapy molds is effective and provides a high local control rate with acceptable toxicity.

show abstract

Feasibility and tolerance of pulsed dose rate interstitial brachytherapy

Cited by 37 publications

References 16 publications

Preliminary Report of Pulsed Dose Rate Brachytherapy in Head-and-Neck Cancer

Preliminary Report of Pulsed Dose Rate Brachytherapy in Head-and-Neck Cancer

Pulsed-Dose Rate Brachytherapy for the Treatment of Endometrial Cancer

Contemporary role of modern brachytherapy techniques in the management of malignant thoracic tumors

Contact Info

Product

Resources

About